A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults

Journal of Clinical Immunology

Volumn 37, Issue 7, 2017, Pages 638-643

  Kumar, Bharat ^a   Aleem, Sohaib ^b   Saleh, Hana ^c   Petts, Jennifer ^d   Ballas, Zuhair K ^a,e  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b South Bend Clinic   (United States)

^c Apex Medical Center   (United States)

^d Iowa Clinic   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokine; Hemophagocytic lymphohistiocytosis; Macrophage activation syndrome; Systemic inflammation

Indexed keywords

ANAKINRA; C REACTIVE PROTEIN; CYCLOSPORIN; CYTOKINE; DEXAMETHASONE; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; MEPREDNISONE; PREDNISONE; STEROID; TOCILIZUMAB; ANTIRHEUMATIC AGENT; CYCLOSPORINE; IMMUNOLOGIC FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL OUTCOME; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; FEMALE; HEMOPHAGOCYTIC SYNDROME; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MACROPHAGE ACTIVATION SYNDROME; MALE; MIDDLE AGED; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; IMMUNOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; CYCLOSPORINE; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME; MALE; MIDDLE AGED; PRECISION MEDICINE; STEROIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85028838913     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-017-0439-x     Document Type: Article

References (18)

1. Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015;26(3):263–80.
2. Trottestam H, Horne A, Arico M, Egeler RM, Filipovich AH, Gadner H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577–84.
3. Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90(3):220–4.
4. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.
5. Shabbir M, Lucas J, Lazarchick J, Shirai K. Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature. Hematol Oncol. 2011;29(2):100–6.
6. Mehta RS, Smith RE. Hemophagocytic lymphohistiocytosis (HLH): a review of literature. Med Oncol (Northwood, London, England). 2013;30(4):740.
7. Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145–59.
8. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484–92.
9. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154–7. https://doi.org/10.1182/blood-2013-02-485623.
10. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275–81.
11. Miettunen PM, Narendran A, Jayanthan A, et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50(2):417–9. https://doi.org/10.1093/rheumatology/keq218.
12. Oto M, Yoshitsugu K, Uneda S, Nagamine M, Yoshida M. Prognostic factors and outcomes of adult-onset hemophagocytic lymphohistiocytosis: a retrospective analysis of 34 cases. Hematol Rep. 2015;7(2):5841.
13. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664–79. https://doi.org/10.1158/2159-8290.CD-16-0040.
14. Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011;121(6):2264–77.
15. Sato T, Terai M, Tamura Y, et al. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res. 2011;51(2–3):170–82. https://doi.org/10.1007/s12026-011-8262-6.
16. Orange JS, Brodeur SR, Jain A, et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest. 2002;109(11):1501–9.
17. Wang Y, Wang Z, Zhang J, et al. Genetic features of late onset primary hemophagocytic lymphohistiocytosis in adolescence or adulthood. PLoS One. 2014;9(9):e107386. https://doi.org/10.1371/journal.pone.0107386. eCollection 2014
18. Cron RQ, Davi S, Minoia F, et al. Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol. 2015;11(9):1043–53. https://doi.org/10.1586/1744666X.2015.1058159.